Case Report

Early Experience of Helical Tomotherapy for Hepatobiliary Radiotherapy

Table 3

Treatment characteristics and dosimetric results.

PatientsRadiation dose
per fraction (/F)
Concurrent capecitabine (mg·m²·day)Median dose to the PTV a PTV a volume (cc)Normal liver volume b (cc)Normal liver V30 c (%)Median normal liver dose (Gy)Median right kidney dose (Gy)

154 Gy
2 Gy/F
no56.6417.71244825.51.7
254 Gy
2 Gy/F
150057.23811726.23725.95.3
360 Gy
2 Gy/F
1500612681424,31212.11.5
4 d 54 Gy
60 Gy
2 Gy/F
150055.5 e
61.6 f
671.9
143.5
1653.97,513.29.7
554 Gy
1.8 Gy/F
160054.1174.6892.917.515.74.4
654 Gy
1.8 Gy/F
no54262.68573022.12.1
760 Gy
2 Gy/F
no61.11211160.11014.31.6
854 Gy
2 Gy/F
15005493.91272.369.74.5
9 d 54 Gy
60 Gy
2 Gy/F
150054 e
59.8 f
275.9
221.7
1484.137.225.64.5

a PTV: planning target volume; b Normal liver volume: liver volume minus PTV; c V30: percentage of the normal liver receiving 30 Gy or more; d For patient 4 and patient 9, two levels of dose were prescribed: 54 Gy to the PTV 1 (gross tumour volume (GTV) + 2 cm margin) and 60 Gy to the PTV2 (GTV + 1 cm margin); e Median dose to the PTV1; f Median dose to the PTV.